Skip to main content Accessibility help
×
×
Home

The effects of systemic steroid therapy on macrophage migration inhibitory factor concentrations in patients with nasal polyps

  • A Ekinci (a1)

Abstract

Objectives

This study aimed to compare serum macrophage migration inhibitory factor concentrations before and after oral steroid therapy in nasal polyps patients, and determine whether there is a difference between pre-treatment macrophage migration inhibitory factor concentrations and healthy individuals.

Methods

The study included 24 patients with nasal polyps and 25 healthy individuals. The patient group received 1 mg/kg oral steroid.

Results

The mean macrophage migration inhibitory factor concentration before oral steroid therapy was 3889.79 pg/ml in the patient group and 2334.52 pg/ml in the control group. Macrophage migration inhibitory factor concentrations were statistically significantly higher in the pre-oral steroid therapy patient group than in the control group (p = 0.017). The mean pre- and post-oral steroid therapy serum macrophage migration inhibitory factor concentrations were 3889.79 pg/ml and 2451.25 pg/ml, respectively. The reduction in macrophage migration inhibitory factor concentrations was statistically significant (p = 0.010).

Conclusion

These findings suggest that concentrations of macrophage migration inhibitory factor may play a role in the pathogenesis of nasal polyps.

Copyright

Corresponding author

Author for correspondence: Dr Adnan Ekinci, Üçtutlar Mh, Ahçılar 16, Sokak, Ada Aparmant B Blok no: 15, 19000, Çorum, Turkey E-mail: draekinci@hotmail.com

Footnotes

Hide All

Dr A Ekinci takes responsibility for the integrity of the content of the paper

Footnotes

References

Hide All
1Koc, C. Nasal Polyps, Otolaryngology, Head and Neck Surgery [in Turkish]. Ankara: Güneş Kitabevi, 2004;609–24
2Keles, B, Cora, T, Acar, H, Arbag, H, Inan, Z, Ozturk, K et al. Evaluation of HLA-A, -B, -Cw, and-DRB1 alleles frequency in Turkish patients with nasal polyposis. Otolaryngol Head Neck Surg 2008;139:580–5
3Settipane, GA, Lund, VJ, Tos, M. Nasal Polyps: Epidemiology, Pathogenesis and Treatment. Providence, RI: Oceanside Publications, 1997
4Calandra, T, Berhagen, J, Metz, CN, Spiegel, LA, Bacher, M, Donnelly, T et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377:6871
5Calandra, T, Roger, T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003;3:791800
6Santos, LL, Morand, EF. The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis. Wien Med Wochenschr 2006;156:1118
7Calandra, T, Bernhagen, J, Mitchell, RA, Bucala, R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994;179:1895–902
8Donn, R, Ray, D. Macrophage migration inhibitory factor: molecular, cellular and genetic aspects of a key neuroendocrine molecule. J Endocrinol 2004;182:19
9Hopkins, C, Browne, JP, Slack, R, Lund, V, Brown, P. The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict? Otolaryngol Head Neck Surg 2007;137:555–61
10Lue, H, Kleemann, R, Calandra, T, Roger, T, Bernhagen, J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 2002;4:449–60
11Kitaichi, N, Shimizu, T, Honda, A, Abe, R, Ohgami, K, Shiratori, K et al. Increase in macrophage migration inhibitory factor levels in lacrimal fluid of patients with severe atopic dermatitis. Graefes Arch Clin Exp Ophthalmol 2006;244:825–8
12Li, C, Ma, H, Ba, Y. The expression and role of MIF, NF-κB and IL-1β in nasal polyps [in Chinese]. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2016;30:220–5
13Delbrouck, C, Gabius, HJ, Vandenhoven, G, Kiss, R, Hassid, S. Budesonide-dependent modulation of expression of macrophage migration inhibitory factor in a polyposis model: evidence for differential regulation in surface and glandular epithelia. Ann Otol Rhinol Laryngol 2004;113:544–51
14Mitchell, R, Bacher, M, Bernhagen, J, Pushkarskaya, T, Seldin, M, Bucala, R. Cloning and characterization of the gene for mouse macrophage migration inhibitory factor (MIF). J Immunol 1995;154:3863–70
15Stathas, T, Athanassiou, S, Drakouli, S, Giannopoulou, E, Mastronikolis, NS, Naxakis, S et al. MIF attenuates the suppressive effect of dexamethasone on IL-6 production by nasal polyp. Eur Rev Med Pharmacol Sci 2013;17:1455–66
16Rossi, AG, Haslett, C, Hirani, N, Greening, AP, Rahman, I, Metz, C et al. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest 1998;101:2869–74
17Nakamaru, Y, Takagi, D, Oridate, N, Furuta, Y, Nishihira, J, Fukuda, S. Macrophage migration inhibitory factor in allergic rhinitis: its identification in eosinophils at the site of inflammation. Ann Otol Rhinol Laryngol 2004;113:205–9
18Kozacı, LD, Chikanza, IC, Eyigör, H, Döğer, F, Kavak, T, Evci, D et al. Effects of topical mometasone furoate therapy on local and systemic macrophage migration inhibitory factor levels in allergic rhinitis patients [in Turkish]. Meandros Med Dent J 2005;6:23–7
19Cvetkovic, I, Al-Abed, Y, Miljkovic, D, Maksimovic-Ivanic, D, Roth, J, Bacher, M et al. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 2005;146:2942–51
20Yang, N, Nikolic-Paterson, DJ, Ng, YY, Mu, V, Metz, C, Bacher, M et al. Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production. Mol Med 1998;4:413–24
21Denkinger, CM, Denkinger, M, Kort, JJ, Metz, C, Forsthuber, TG. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J Immunol 2003;170:1274–82
22Matsui, Y, Okamoto, H, Jia, N, Akino, M, Uede, T, Kitabatake, A et al. Blockade of macrophage migration inhibitory factor ameliorates experimental autoimmune myocarditis. J Mol Cell Cardiol 2004;37:557–66
23Al-Abed, Y, Dabideen, D, Aljabari, B, Valster, A, Messmer, D, Ochani, M et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem 2005;280:36541–4
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The Journal of Laryngology & Otology
  • ISSN: 0022-2151
  • EISSN: 1748-5460
  • URL: /core/journals/journal-of-laryngology-and-otology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed